Scinovex
articleTop 1% cited

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

Clinical Pharmacology & Therapeutics · 2003 · Vol. 73(6) · pp. 554–565
Yohei Nishizato

Abstract

Certain commonly occurring single-nucleotide polymorphisms in OATP-C, such as T521C (Val174Ala), are likely to be associated with altered pharmacokinetics of pravastatin. Large clinical studies are needed to confirm these observations.

Drug Transport and Resistance MechanismsPharmacological Effects and Toxicity StudiesPharmacogenetics and Drug MetabolismOrganic anion-transporting polypeptideNonsynonymous substitutionOrganic anion transporter 1PravastatinPharmacokineticsSingle-nucleotide polymorphismGeneBiologyPharmacologyTransporter

MeSH terms

AdultAllelesBiotransformationDNAGene FrequencyHaplotypesHumansJapanTerminology as TopicPolymorphism, GeneticPravastatinHydroxymethylglutaryl-CoA Reductase InhibitorsArea Under CurveReverse Transcriptase Polymerase Chain ReactionLiver-Specific Organic Anion Transporter 1
Citations
511
FWCI
18.44
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
Cited by
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Clinical Pharmacology & Therapeutics · 2006 · 842 citations
Importance of P-glycoprotein at blood–tissue barriers
Trends in Pharmacological Sciences · 2004 · 582 citations
Membrane transporters in drug development
Nature Reviews Drug Discovery · 2010 · 3,297 citations
Transporters and drug therapy: Implications for drug disposition and disease
Clinical Pharmacology & Therapeutics · 2005 · 496 citations
Impact of OATP transporters on pharmacokinetics
British Journal of Pharmacology · 2009 · 976 citations
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.